©2024 Stanford Medicine
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata
Recruiting
Trial ID: NCT03898479
Purpose
The overall objectives of the study are to evaluate long-term safety of CTP-543 and to assess
long-term effects of CTP-543 on treating hair loss in adult patients with chronic, moderate
to severe alopecia areata.
Official Title
A Multicenter, Open-Label, Extension Study to Assess the Long-Term Safety and Efficacy of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata
Stanford Investigator(s)
Justin M Ko, MD, MBA
Clinical Professor, Dermatology
Eligibility
Inclusion Criteria:
- Have completed 24 weeks of treatment in a previous qualifying CTP-543 clinical trial
Exclusion Criteria:
- Active scalp inflammation, psoriasis, or seborrheic dermatitis requiring topical
treatment to the scalp, significant trauma to the scalp, or untreated actinic
keratosis
- Females who are nursing, pregnant, or planning to become pregnant while in the study,
and for 30 days after last dose of study medication
- Donation of blood at any point throughout the study and for 30 days after last dose of
study medication
Intervention(s):
drug: CTP-543
Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305